Get started

Biotech

EVAX - Evaxion BiotechThe Biotech company Evaxion Biotech, EVAX, who develop drugs based on AI platforms, is poised to publish data from its phase 1/2a trials of EVX-01 and EVX-02 in the first half of 2021. According to Yahoo Finance there are currently two analysts with price targets for the share, $18 and $23. Evaxion is an AI-immunology platform company decoding the human immune system to discover and develop novel immunotherapies for cancer and infectious diseases. Evaxion have developed an AI-immunology core technology to deeply understand the biological processes relevant for engaging the immune system aiming to harness its powers through novel immunotherapies. Evaxions scalable AI-immunology core technology enables broad applicability across diseases with immunological components. With deep insights into the biological processes of the immune system, Evaxion bridges technology, engineering expertise and drug development know-how to bring novel immunotherapies to patients. Evaxion uses its proprietary AI-immunology platform to simulate the human immune system and generate predictive models to identify and develop unique immunotherapies and thereby revolutionizing the process of drug discovery and development. PIONEER PIONEER is Evaxions proprietary AI platform for the rapid discovery and design of patient-specific neoepitopes used to derive immuno-oncology therapies. It has been shown that neoepitopes, which arise from patient-specific tumor mutations, play a critical role in T-cell mediated antitumor immune response. EDEN EDEN is Evaxions second AI platform that rapidly identifies novel, highly protective antigens for the use in pathogen-specific prophylactic vaccines against bacteria. EDEN has been designed to rapidly identify those antigens that will trigger a robust protective immune response against almost any bacterial infectious disease. In addition, EDEN redesigns identified antigens to optimize their antigenic and structural properties as well prepare them for production, which allow us to move antigen candidates into the clinic far faster than traditional, vaccine discovery approaches. EDEN has been pre-clinically validated in seven different pathogens in mouse infection models, and Evaxion believes that their approach can be used to target almost any bacterial infection and rapidly enables the discovery and development of vaccine candidates. RAVEN RAVEN is Evaxions third proprietary AI platform that brings their unique, machine learning approach to vaccine design and development for viral diseases. RAVEN combines the essential AI tools from our PIONEER platform with structural bioinformatic tools from EDEN to arrive at a novel potent T- and B-cell vaccine design for emerging and mutating viral diseases. Pipeline Evaxion’ pipeline of immunotherapies addresses two of the biggest unmet medical needs worldwide – cancer and infectious diseases. Evaxion currently has four products in their pipeline. Two in pre-clinical and two in phase 2 trials. Evaxions lead candidates are EVX-01, for the treatment of metastatic and unresectable melanoma, non-small cell lung cancer, and bladder cancer; and EVX-02, for the adjuvant treatment of melanoma. EVX-01 and EVX-02 are both currently in Phase 1/2a trials, with data expected in the 1H21. Evaxion intends to expand their current pipeline both within cancer and infectious diseases, and into other disease areas as we continue to explore new frontiers in AI-immunology. IPO Evaxion raised $30 million by offering 3 million ADSs at $10, the low end of the range of $10 to $12. The company offered 0.3 million more ADSs than anticipated. Evaxion was listed on the NASDAQ on 5. february 2021.
NASDAQ:EVAXLong
by stensgaard81
Familiar T/A on ITRM Well, doesn't this look familiar? ITRM tested is previous level of support AND resistance in a wide channel today. IDK what the sell-off was but I'm guessing the re-entry had something to do with speculation on the FDA data set to come out next month. "At the end of May, Iterum provided an update on its New Drug Application with the U.S. Food and Drug Administration. Currently, the NDA is still under review by the FDA, and the PDUFA goal date is July 25th, 2021. Since the application review for Sulopenem is on track at the moment, ITRM stock is performing well as a result. ITRM stock price has nearly doubled in the last month." Not sure if it gets the approvals necessary but "buy the rumor" might be playing a role here. Quote Source: Top 9 Penny Stocks With High Volume to Watch Right Now
NASDAQ:ITRM
by PennyStocks101
2
$CARA Target 17.68 for 24.42%$CARA Target 17.68 for 24.42% Or double position at 10.74 I'm not sure if I published this one when I first bought on that hellacious dip, haha. 🤣 Anyway, it looks like it found a little bit of support here so, might as well publish it here This might not be a trade you want to play... I will post better ones... just for reference here. — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. I start every position with 1% of my account and build from there as needed and as possible. I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed. GL and happy trading. I finally added my YouTube Training Video to my profile tagline since I’m not allowed to on here. It’s a quick 15 minute training video on how to set up your chart and how to spot opportunities. So check here first but If you have questions just message me.
NASDAQ:CARALong
by SPYder_QQQueen_Trading
$LCTX biotech company analysis *This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* My team has been following clinical-stage biotech company $LCTX for the past few months. $LCTX pipeline looks very promising. We believe that current price levels are undermining the companies potential. We entered $LCTX on 5/14/21 at $2.23 per share and have been holding ever since. Following its correction from its 52-week high of $3.13 $LCTX now sits at $2.80 per share. My team averaged up on our $LCTX position this morning at $2.70 per share and intend to take profit at $4.20. ORIGINAL ENTRY: $2.23 AVERAGING UP AT: $2.70 TAKE PROFIT: $4.20 STOP PROFIT LOSS: $2.50 If you want to see more, please like and follow us @SimplyShowMeTheMoney
AMEX:LCTXLong
by SimplyShowMeTheMoney
Here We Go (Again?) With ATOSThis is familiar territory with ATOS . Not only is there a very clear and significant support level on the chart, there's also a multi-year level of resistance the ATOS is sitting at right now. The biggest question is Now What? " Earlier this month, Atossa revealed data from a Phase 2 Endoxifen study in breast cancer. It met primary and secondary endpoints. The Phase 2 study was conducted on behalf of Atossa by Avance Clinical, a leading Australian CRO. Based on the results, the company also discussed its plan to apply to the FDA for approval to begin a clinical study in the US 'as soon as possible.' With meaningful results and potential for more clinical trials in the US, ATOS could be on the list of biotech penny stocks on Robinhood to watch this summer ." Quote Source: 7 Penny Stocks On Robinhood To Watch In June 2021
NASDAQ:ATOS
by PennyStocks101
13
RGLS Showing Interesting LevelsRGLS continues pivoting around that 618 Fib line. Overall, it has held a clear uptrend despite the pullback. Trend line lines up almost perfectly with the latest higher lows put in. RNA companies remain a focus. In this case, it's not covid but kidney diseases. "In mid-May, Regulus Therapeutics announced an incremental update of its autosomal dominant polycystic kidney disease program. The CEO of the company, Jay Hagan said, “As previously reported, the ninth and final patient was trending well at the end of the dosing period and saw their polycystin levels continue to rise until study completion, twenty-eight days after the last dose. This pattern was generally consistent across the first cohort and further enhanced the overall mean changes from baseline for both biomarkers." PLUS upcoming presentation of RGLS4326 for the treatment of ADPKD at the PKD Connect Conference 2021 this Friday (6/25) could be something to keep in mind right now too. Quote Source: 7 Hot Penny Stocks to Watch That Are Trending Right Now
NASDAQ:RGLS
by PennyStocks101
This looks...Familiar on ATOSThis is a very interesting level for ATOS right now. The last two times before this most recent instance the stock failed to break through and hold this level. It was able to do that briefly this year but unsustainable. After consolidating this last time around, what's the catalyst to actually spark a firm move? I think a lot will come down to the next steps for AT-301 to be honest: "Recently ATOS has received phase 2 initiation approval from the Swedish Medical Product Agency for its oral Endoxifen. This drug targets mammographic breast density (MBD), to reduce and eradicate potential tumors. MBD affects millions worldwide and can reduce the effectiveness of mammograms...Doctors around the world depend on mammogram studies to detect cancer through breast density. With a drug such as Endoxifen, it would increase the ability for earlier diagnosis, which in turn could reduce breast cancer incidence... This is a large breakthrough for the company and considering the incidence of breast cancer around the world, Endoxifen could be a big deal moving forward. Investors should stay up to date with any news regarding this compound, as it is Atossa’s flagship product. However, it does have a sizable pipeline that includes a Covid-19 nasal spray treatment known as AT-301." Quote Source: 4 Top Biotech Penny Stocks To Watch In The Second Half Of June 2021
NASDAQ:ATOS
by PennyStocks101
$MBRX Moleculin biotech $MBRX seems to have grit for sellThe Marketmiracle advisor reported last night a major entry on the stock $MBRX with a potential profit of 300% approximately The company Moleculin Biotech has several active trials all in the field of cancer research and recently also against covid, has recently presented quarterly and annual data far above the expectations of analysts. Recently a reverse split of the stock has also been carried out that reduces the number of titles in circulation. In fact, today the Miracle Viewer indicator that analyzes the graph in search of interests in the market of large players shows an increase in LONG positions by the institutions so you could implement an upward price action. Analyzing the chart, the title seems to have some obstacles along the way but if the interests from the big will remain high will probably be surpassed with limited retracements, according to the signal of Marketmiracle the stock could go even further pushing at the price of 15,50 USD but I would not want in my graphical analysis to exceed the level I indicate as target as it is already a remarkable increment and during the path the title could lose strength. I will try to free cash and enter the stock also because at the moment the balance seems to be shifting a lot on pharmaceuticals and biotech companies so personally I think this is a good opportunity. ( see related other ideas on other biotech and pharma titles ) We will see in the next hours and days if the forecast of Marketmiracle will prove effective. This idea is based on the signal generated by the Marketmiracle advisor whose link you can find by scrolling at the bottom of this page.
NASDAQ:MBRXLong
by MarketMiracleAdvisor
2
$CAPR Target 7.61 for 42.51% $CAPR Target 7.61 for 42.51% Or next add level is at 3.07 — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. I start every position with 1% of my account and build from there as needed and as possible. I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed. GL and happy trading.
NASDAQ:CAPRLong
by SPYder_QQQueen_Trading
ENTX - Entera Bio Ltd on huge run - possible double againI bought this one several days ago and there is still a huge amount of upside. If it can get through the $4.30 and $4.80 resistance a double is a real deal. They have had solid revenues the last 2 Q and are based in Isreal. They have partnered in a project with Amgen and have been around I think since 2003. The Timeframes tell the story and the flow of the chart and long build up shows possible huge rewards near term. I am long for this company, but relatively short for this run...I think by next week we will be above $5 or $5.50.
NASDAQ:ENTXShort
by sid72
2
ONTX Onconova Therapeutics good results = good growthThere’s no reason in the world that a biopharmaceutical company like $ONTX that operates cancer research and has a very good quarterly should be stationary at the same price, rather lower than the time at which the quarterly report was submitted, which was excellent and above the expectations of the analyses. After a vertical takeoff he retracted his full price going, at present, to position himself about a 15% below. In addition, there has been a reverse split of stocks that reduces the number of shares outstanding, so the value of each individual share should increase significantly. The advisor Marketmiracle has in fact emitted a signal LONG on the Stock to the price of 6,64 usd with a target of 622 usd that is a vertical takeoff of 9268% identifying a massive entry of capitals and of interest LONG on the Stock from some great investor. Let’s just stay grounded and figure it out on the graph. The graph tells us that surely the title has the ability to climb without virtually obstacles to the resistance indicated, we see them further signs and we will reason whether the great climb should continue or not. A greater interest in biotechs and pharmaceuticals that for some time had been put aside gives us more reason to believe that the increase in price can actually take place ( see related ideas ) This idea is based on the signal generated by the Marketmiracle advisor whose link you can find by scrolling at the bottom of this page.
OLong
by MarketMiracleAdvisor
7
APRE MASSIVE MOVE COMING JULY 16 CALL OPTIONSFirst, this stock is just beaten down in no way shape or form should it be at this price. 30% shorted really the only reason. Beat EPS decent ER nothing unordinary for a Bio stock. This is the definition of primed and ready to go. Extremely obvious with the candle build up at the bottom of the pattern. Easily a $5 target. Call options July 16th 7.50 call. Yes it seems weird since it's not a "liquid option" but is traded and will gain IV and price movement which is how you make the real profits. Even buying the stock it clearly has $5-$7 written all over it let alone a MASSIVE gap to fill.
NASDAQ:APRELong
by DigitalData
4
I imagine this... probably ... and it’s just the beginning.According to the indicator at the base of the advisor Marketmiracle the CLVS stock is accumulating capitals and is ready for an explosion. Clovis Oncology is one of the best-selling low-cost titles but produces a drug capable of improving the lives of cancer patients worldwide. Clearly the money devoted to biotech and pharmaceutical companies during the covid period was directed to vaccine manufacturers but now, that the clouds are clearing up and the covid danger seems to have drifted away, it seems to be heading back to what are the possible cures for the diseases of the century, namely cancer, This is also demonstrated by the recent rise in prices of $AHT, which is a cancer care company ( see related idea) I imagine a movement of the title as the one indicated in the graph, but I have the feeling that it will only be the beginning, the company a few years ago priced much but much more and its trails are successful as demonstrated by the recent results. Investing in a society like this is also a way to help medicine and the entire human race.. I did a search on the fundamental analysis sites that I use as a reference and it seems according to their analysts that the current price of Clovis Oncology is absolutely below the right value, which is given around 50 USD i.imgur.com I certainly put a chip on Clovis ... I think it’s a great opportunity. Scrolling at the bottom of this page you will find the advisor Market Miracle who gave a few days ago the input signal on $CLVS.
CLong
by MarketMiracleAdvisor
5
Short Squeeze - CMMBIdea for Chemomab Therapeutics Ltd.: - 131% borrow fee for shares. 47 shares available for borrow, according to iborrowdesk. - Bottom of Risk Range: - S3 Filing Sales Agreement with Cantor Fitzgerald & Co. dated Apr 30, 2021. fintel.io - Cantor Fitzgerald assigned overweight rating on CMMB and raised price target to $45. www.marketbeat.com - Good short squeeze material. - Non Optionable. Bought the shares $16.69 Expect share dilution $40-$50 GLHF - DPT
NASDAQ:CMMBLong
by UnknownUnicorn1043646
3
High Traffic Resistance & Upcoming CatalystThis week will be a potentially big one (in either direction for AGEN imo and it will come down to the data to tell which way the stock breaks...or breaks down. This week, AGEN stock could be on the list of penny stocks to watch. Two posters will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting from June 4 – 8, 2021.The focus will likely be on the specifics of the trial and its design. “We are encouraged by the differentiated qualities of our anti-PD-1 balstilimab both in the clinic and in preclinical…Our novel CD137, AGEN2373, has been well-tolerated in this dose-escalation trial, and we look forward to advancing it into combinations for potential benefit to patients,” said Steven O’Day, MD, Chief Medical Officer at Agenus, in a PR last week. Quote Source: Hot Penny Stocks To Buy On Robinhood With Upcoming Events This Week
NASDAQ:AGEN
by PennyStocks101
Humanigen $HGEN is ready for a breakoutThese past weeks we saw a lot of action regarding $HGEN - not that much pricewise, but more on a fundamental basis like the long awaited news about the date for the Emergency-Use-Authorization (EUA), identified as a key driver for demand and price action. Humanigen intends to request the EUA by June 2021. Looking at the chart, the price did not react as much to the news, most likely because of anticipation, whether they will receive the EUA or not (I assume they will). Humanigen has done a great job fulfilling the prerequisites (published Phase 3 data looks promising) and they recently had a meeting with the FDA to clarify the scope (www.biospace.com). Several rating companies have set the target at 40$, but looking at the chart and institutional interest there is clearly a bit more upwards potential than that. 30$ has been reached previously and with Blackrock increasing their position, as well as HGEN being the 5th largest holding in the XBI ETF a target of 60$, 86$ and 102$ is more likely. The big companies have done a great job in increasing their position without moving the stock's price too much. Right now we have a tight trading range and 20$ is working as a light resistance. A shakeout also occured yesterday and it is possible that more might follow. These are quite normal, as big companies try to improve their position. -This is no financial advice- For transparency: I am invested in $HGEN with 1/10 of my account size. I always keep buffer cash and never go all in!
HLong
by RedFoxTrading